Development of Nanocarriers in Drug Treatment of Non-alcoholic Fatty Liver Disease

Non-alcohol fatty liver disease(NAFLD) has become one of the most common liver diseases in the world. The clinical manifestation is liver steatosis, which gradually deteriorates into end-stage liver disease like nonalcoholic steatohepatitis (NASH), liver cirrhosis and liver cancer. Currently, the drugs used to treat NAFLD mainly include hepatoprotective drugs, insulin sensitizers, lipid-lowering drugs, antioxidants, etc., but the therapeutic effect has not yet met the sanative requirements. Nanocarriers are an important part of nanomedicine. They have the advantages of increasing drug solubility, controlling drug release, promoting oral absorption, improving drug treatment effects, and reducing drug toxicity. They have great potential of application in NAFLD drug therapy and need to be further studied.